C 반응성 단백질 검사 시장 규모, 점유율, 동향 분석 보고서 : 어세이 유형별, 검출 범위별, 질환 영역별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

C-Reactive Protein Testing Market Summary

The global C-reactive protein testing market size was estimated at USD 5.34 billion in 2025 and is projected to reach USD 6.08 billion by 2033, growing at a CAGR of 1.68% from 2026 to 2033, due to the increasing demand for precision medicine. C-reactive protein is an acute-phase reactant whose levels rise during the early stage of a disease condition, leading to inflammation in the body.

The increasing burden of chronic diseases such as cardiovascular disorders, diabetes, and autoimmune conditions is a major market driver. In addition, technological advancements in CRP testing, such as innovations in diagnostic techniques, accuracy of the tests, and ease of accessibility, contribute to the major drivers for this market.

The development of point-of-care (POC) CRP testing has transformed disease diagnosis by allowing for quick, on-site testing in clinics, pharmacies, and even home-care environments. These advancements have improved the efficiency of healthcare delivery by shortening result turnaround times and facilitating quicker clinical decision-making. As the demand for personalized medicine increases, technological advancements in CRP testing are anticipated to further propel market growth by enhancing patient outcomes and streamlining diagnostic procedures. According to a report in July 2024, Cornell University proposed an electrochemical impedance spectroscopy (EIS)-based sensor for real-time, fast, and sensitive detection of C-reactive Protein in interstitial fluid (ISF) using minimally invasive microneedle arrays. This sensor, which could be integrated into a wearable device similar to continuous glucose monitoring, offers a non-invasive, affordable, and simple method for CRP detection.

CRP testing serves as an essential tool for early diagnosis of infections, cardiovascular conditions, and inflammatory disorders, allowing for timely medical intervention. Governments and healthcare organizations around the globe are actively encouraging regular screening programs to detect individuals at risk before serious complications develop. In addition, growing health awareness among individuals has resulted in a higher demand for preventive diagnostic tests, such as CRP testing, as part of regular health check-ups. The shift towards preventive healthcare and early disease detection has been a key factor driving market growth. As healthcare systems prioritize lowering long-term treatment expenses and enhancing patient outcomes, the early detection of inflammation-related diseases has become increasingly crucial. The increasing focus on proactive health management will further accelerate the adoption of CRP testing in various healthcare settings.

One of the key drivers for expansion in the market of C-reactive protein testing is the increasing adoption of these tests and the expansion oftheir application in emerging markets. As chronic diseases become more prevalent in these regions due to lifestyle changes, urbanization, and aging populations, the demand for affordable and accessible diagnostic solutions is growing. CRP testing is becoming a standard component of primary healthcare screenings, especially in regions with high rates of infectious diseases and inflammatory disorders. The expansion of diagnostic laboratory services, along with the growing availability of point-of-care testing in rural and underserved areas, is expected to drive the market in these regions further. As healthcare systems in emerging markets continue to advance, the demand for CRP testing will continue to rise, fueling global market growth.

Beyond technological advancements, C-reactive protein testing continues to be integral in clinical research applications. For example, in August 2024, a study presented at the European Society of Cardiology Companies utilized hsCRP (high-sensitivity) measurements to assess cardiovascular risks in women. The findings suggest that evaluating hsCRP levels starting in a woman's 30s can better predict future cardiovascular events, highlighting the importance of early intervention and personalized healthcare strategies. These developments underscore the dynamic nature of CRP testing, reflecting its expanding role in both market growth and clinical practice.

Global C-Reactive Protein Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global C-reactive protein testing market report based on assay type, detection range, disease area, end-use, and region:

• Assay Type Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoturbidimetric Assay
• ELISA
  • Clinical
  • Nonclinical
• Chemiluminescence Immunoassay
• Others
• Detection Range Outlook (Revenue, USD Million, 2021 - 2033)
• hs-CRP
• Conventional CRP
• cCRP
• Disease Area Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Clinics
  • By Entity
  • Physician Offices
  • Small Clinics
  • Others
  • By Settings
  • Urban Setting
  • Rural Setting
• Hospitals
  • Urban Setting
  • Rural Setting
• Laboratories
  • Urban Setting
  • Rural Setting
• Assisted Living Healthcare Facilities
  • Urban Setting
  • Rural Setting
• Home
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Assay Type
  • 1.2.2. Detection Range
  • 1.2.3. Disease Type
  • 1.2.4. End Use
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. C-Reactive Protein Testing Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising incidence of chronic and infectious diseases
    • 3.3.1.2. Increasing demand for point-of-care diagnostics
    • 3.3.1.3. Growing demand for portable and automated C-reactive proteins
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Lower detection limit
    • 3.3.2.2. Limitations associated with C-reactive protein techniques
• 3.4. C-Reactive Protein Testing Market Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. C-Reactive Protein Testing Market: Assay Type Estimates & Trend Analysis

• 4.1. C-reactive Protein Testing Market: Assay Type Movement Analysis
• 4.2. Immunoturbidimetric Assay
  • 4.2.1. Immunoturbidimetric Assay Market, 2021 - 2033 (USD Million)
• 4.3. ELISA
  • 4.3.1. ELISA Market, 2021 - 2033 (USD Million)
  • 4.3.2. Clinical ELISA
    • 4.3.2.1. Clinical ELISA Market, 2021 - 2033 (USD Million)
  • 4.3.3. Nonclinical ELISA
    • 4.3.3.1. Nonclinical ELISA Market, 2021 - 2033 (USD Million)
• 4.4. Chemiluminescence Immunoassay
  • 4.4.1. Chemiluminescence Immunoassay Market, 2021 - 2033 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. C-Reactive Protein Testing Market: Detection Range Estimates & Trend Analysis

• 5.1. C-reactive Protein Testing Market: Detection Range Movement Analysis
• 5.2. High Sensitivity C-reactive Protein (hs-CRP)
  • 5.2.1. High Sensitivity C-reactive Protein (hs-CRP) Market, 2021 - 2033 (USD Million)
• 5.3. Conventional CRP
  • 5.3.1. Conventional CRP Market, 2021 - 2033 (USD Million)
• 5.4. Cardiac CRP (cCRP)
  • 5.4.1. Cardiac CRP (CCRP) Market, 2021 - 2033 (USD Million)

Chapter 6. C-Reactive Protein Testing Market Disease Area Estimates & Trend Analysis

• 6.1. C-reactive Protein Testing Market: Disease Area Movement Analysis
• 6.2. Cardiovascular Diseases
  • 6.2.1. Cardiovascular Diseases Market, 2021 - 2033 (USD Million)
• 6.3. Cancer
  • 6.3.1. Cancer Market, 2021 - 2033 (USD Million)
• 6.4. Rheumatoid Arthritis
  • 6.4.1. Rheumatoid Arthritis Market, 2021 - 2033 (USD Million)
• 6.5. Inflammatory Bowel Disease
  • 6.5.1. Inflammatory Bowel Disease Market, 2021 - 2033 (USD Million)
• 6.6. Endometriosis
  • 6.6.1. Endometriosis Market, 2021 - 2033 (USD Million)
• 6.7. Lupus
  • 6.7.1. Lupus Market, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. C-Reactive Protein Testing Market End Use Estimates & Trend Analysis

• 7.1. C-reactive Protein Testing Market: End-use Movement Analysis
• 7.2. Clinics
  • 7.2.1. Clinics Market, 2021 - 2033 (USD Million)
  • 7.2.2. Clinics, by entity
    • 7.2.2.1. Physician offices
      • 7.2.2.1.1. Physician Offices Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Small clinics
      • 7.2.2.2.1. Small Clinics Market, 2021 - 2033 (USD Million)
    • 7.2.2.3. Others
      • 7.2.2.3.1. Others Market, 2021 - 2033 (USD Million)
  • 7.2.3. Clinics, by setting
    • 7.2.3.1. Urban setting
      • 7.2.3.1.1. Urban Setting Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Rural settings
      • 7.2.3.2.1. Rural Settings Market, 2021 - 2033 (USD Million)
• 7.3. Hospitals
  • 7.3.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 7.3.2. Urban setting
    • 7.3.2.1. Urban Setting Market, 2021 - 2033 (USD Million)
  • 7.3.3. Rural settings
    • 7.3.3.1. Rural Settings Market, 2021 - 2033 (USD Million)
• 7.4. Laboratories
  • 7.4.1. Laboratories Market, 2021 - 2033 (USD Million)
  • 7.4.2. Urban setting
    • 7.4.2.1. Urban Setting Market, 2021 - 2033 (USD Million)
  • 7.4.3. Rural settings
    • 7.4.3.1. Rural Settings Market, 2021 - 2033 (USD Million)
• 7.5. Assisted Living Healthcare Facilities
  • 7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
  • 7.5.2. Urban setting
    • 7.5.2.1. Urban Setting Market, 2021 - 2033 (USD Million)
  • 7.5.3. Rural settings
    • 7.5.3.1. Rural Settings Market, 2021 - 2033 (USD Million)
• 7.6. Home
  • 7.6.1. Home Market, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. C-Reactive Protein Testing Market: Regional Estimates & Trend Analysis

• 8.1. C-Reactive Protein Testing Market Share, By Region, 2024 & 2033 (USD Million)
• 8.2. North America
  • 8.2.1. North America C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Target Disease Prevalence
    • 8.2.2.3. Competitive Scenario
    • 8.2.2.4. Regulatory Framework
    • 8.2.2.5. Reimbursement Scenario
    • 8.2.2.6. U.S. C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. Canada C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Reimbursement Scenario
    • 8.2.4.6. Mexico C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. Reimbursement Scenario
    • 8.3.2.6. UK C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. Germany C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. France C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. Italy C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Spain C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Denmark C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Sweden C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Norway C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Reimbursement Scenario
    • 8.4.2.6. Japan C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. China C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. India C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. Australia C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. South Korea C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Thailand C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Reimbursement Scenario
    • 8.5.2.6. Brazil C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Argentina C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Reimbursement Scenario
    • 8.6.2.6. South Africa C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. Saudi Arabia C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. UAE C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. Kuwait C-Reactive Protein Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
• 9.5. Abbott
  • 9.5.1. Participant's Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Developments/ Strategic Initiatives
• 9.6. Siemens Healthineers AG
  • 9.6.1. Participant's Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Developments/ Strategic Initiatives
• 9.7. Danaher Corporation
  • 9.7.1. Participant's Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Developments/ Strategic Initiatives
• 9.8. Quest Diagnostics
  • 9.8.1. Participant's Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Developments/ Strategic Initiatives
• 9.9. Getein Biotech, Inc.
  • 9.9.1. Participant's Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Developments/ Strategic Initiatives
• 9.10. Merck KGaA
  • 9.10.1. Participant's Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Developments/ Strategic Initiatives
• 9.11. Zoetis
  • 9.11.1. Participant's Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Developments/ Strategic Initiatives
• 9.12. F. Hoffmann-La Roche AG
  • 9.12.1. Participant's Overview
  • 9.12.2. Financial Performance
  • 9.12.3. Product Benchmarking
  • 9.12.4. Recent Developments/ Strategic Initiatives
• 9.13. Ortho Clinical Diagnostics
  • 9.13.1. Participant's Overview
  • 9.13.2. Financial Performance
  • 9.13.3. Product Benchmarking
  • 9.13.4. Recent Developments/ Strategic Initiatives
• 9.14. Thermo Fisher Scientific, Inc.
  • 9.14.1. Participant's Overview
  • 9.14.2. Financial Performance
  • 9.14.3. Product Benchmarking
  • 9.14.4. Recent Developments/ Strategic Initiatives
• 9.15. HORIBA, Ltd
  • 9.15.1. Participant's Overview
  • 9.15.2. Financial Performance
  • 9.15.3. Product Benchmarking
  • 9.15.4. Recent Developments/ Strategic Initiatives
• 9.16. Randox Laboratories Ltd.
  • 9.16.1. Participant's Overview
  • 9.16.2. Financial Performance
  • 9.16.3. Product Benchmarking
  • 9.16.4. Recent Developments/ Strategic Initiatives
• 9.17. Boditech Med, Inc.
  • 9.17.1. Participant's Overview
  • 9.17.2. Financial Performance
  • 9.17.3. Product Benchmarking
  • 9.17.4. Recent Developments/ Strategic Initiatives
• 9.18. Aidian
  • 9.18.1. Participant's Overview
  • 9.18.2. Financial Performance
  • 9.18.3. Product Benchmarking
  • 9.18.4. Recent Developments/ Strategic Initiatives